From pharming.com November 14, 2016 News, Press Release

Pharming announces the presentation of the results of the RUCONEST® Phase II study for prophylaxis of Hereditary Angioedema attacks

Leiden, The Netherlands, 14 November 2016: Pharming Group N.V. (the “Company”) (EURONEXT: PHARM) today announced that the results of its “Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human C1 Inhibitor for Prophylaxis of Hereditary Angioedema Attacks”, were presented by Marco Cicardi, Professor of Internal Medicine University of Milan, Hospital L. Sacco Milan and co-prinicipal investigator for the study. The presentation was held during the American College of Allergy, Asthma and Immunology 2016 Scientific Meeting (“ACAAI”) meeting in San Francisco yesterday afternoon. The presentation can be found on our website, here.

Read full article


24_7_140


For HAE Emergency:

If you are having an HAE medical emergency, please hang up and dial 911 immediately. For non- emergencies please contact your HAE treating doctor.


For non-emergency questions
– contact a Patient Advocate:

(866) 798-5598

Take action

– and make a difference


  Join our family – become a member of HAEA

  Call our Patient Advocates

  Join the HAEA Café

  Get a referral to an HAE Physician

  Become an Advocate for HAEA

  Have your family checked for HAE

  Join our group on Social Media

  Participate in an event

Participate in our Scientific Registry

  Shop for merchandise

  Volunteer

  Share your HAE story